AEZS (zentaris.com) Multiplikator Forward P/S

Aeterna Zentaris (AEZS) relies on steady demand, although geopolitics and sanctions create risks for supplies and testing. The company's expected P/S reflects valuation dynamics relative to future revenues, where 7.40 serves as the current parameter value. Stable pricing is supported by a unique growth hormone test, while the development strategy is based on the independent deployment of a sales network.

The assessment of investment reliability for assets is based on comparing current capitalization with expected cash flows. The ratio of market value to projected revenue, represented by the forward P/S ratio, allows for an evaluation of the scaling efficiency of the Aeterna Zentaris (AEZS) orphan portfolio following the merger, helping investors distinguish speculative noise from the actual synergy of R&D assets reflected in the dynamics of this chart.